Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Isaacs

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
JCO Oncology Practice|June 26, 2026
Expanding Cellular Therapy for Solid TumorsJames M Isaacs
Journal for Immunotherapy of Cancer|March 3, 2026
Priorities for local immunotherapy research and drug developmentJames M Isaacs, Jason Luke
Biorxiv : the Preprint Server for Biology|May 19, 2023
Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T cell functionSean R McCutcheon, Adam M Swartz, Michael C Brown, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysisCameron Wood, Liliana Lyniv, James M Isaacs, et al.
Nature Genetics|November 9, 2023
Transcriptional and epigenetic regulators of human CD8<sup>+</sup> T cell function identified through orthogonal CRISPR screensSean R McCutcheon, Adam M Swartz, Michael C Brown, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
JCO Oncology Practice|June 26, 2026
Expanding Cellular Therapy for Solid TumorsJames M Isaacs
Journal for Immunotherapy of Cancer|March 3, 2026
Priorities for local immunotherapy research and drug developmentJames M Isaacs, Jason Luke
Biorxiv : the Preprint Server for Biology|May 19, 2023
Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T cell functionSean R McCutcheon, Adam M Swartz, Michael C Brown, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysisCameron Wood, Liliana Lyniv, James M Isaacs, et al.
Nature Genetics|November 9, 2023
Transcriptional and epigenetic regulators of human CD8<sup>+</sup> T cell function identified through orthogonal CRISPR screensSean R McCutcheon, Adam M Swartz, Michael C Brown, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Pageof 1